New follicular lymphoma treated with radiation plus antibody
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether adding a targeted antibody to standard radiation can help people with early-stage, newly diagnosed follicular lymphoma. It aims to control the lymphoma more effectively while keeping treatment safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older, and you have follicular lymphoma that tests positive for CD20 (a marker on the lymphoma cells).
- Your lymphoma has not been treated yet with radiation, chemotherapy, or immunotherapy.
- Your cancer stage is early (stage I or II) based on PET scan imaging.
- Your lymphoma is limited in size, with the largest lymph node/area measuring 7 cm or less.
- You can do usual activities fairly well (ECOG 0–2) and have blood counts that are high enough (ANC, platelets, and hemoglobin meet set minimums).
- If you can become pregnant (or someone could become pregnant from you), you must use effective birth control during treatment and for 18 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding obinutuzumab (an antibody medicine) to local radiation works better than radiation alone in early-stage follicular lymphoma. It aims to improve disease control while keeping treatment safe.
This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
This study tests a combination of two targeted antibody therapies for people newly diagnosed with follicular lymphoma. It aims to see if this combination is effective and safe for controlling the disease.
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
This trial tests combining radiation therapy with a drug called glofitamab (a type of immunotherapy) for patients whose diffuse large B-cell lymphoma (DLBCL) has returned or stopped responding to previous treatments. The goal is to see if adding radiation to this newer drug helps control the cancer better.
Hear when a new Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.